» Articles » PMID: 26921377

Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death

Abstract

Background: The effectiveness of implantable cardioverter-defibrillators (ICDs) for primary prevention of sudden death in patients with an ejection fraction (EF) ≤ 35% and clinical heart failure is well established. However, outcomes after replacement of the ICD generator in patients with recovery of EF to >35% and no previous therapies are not well characterized.

Methods And Results: Between 2001 and 2011, generator replacement was performed at 2 tertiary medical centers in 253 patients (mean age, 68.3 ± 12.7 years; 82% men) who had previously undergone ICD placement for primary prevention but subsequently never received appropriate ICD therapy. EF had recovered to > 35% in 72 of 253 (28%) patients at generator replacement. During median (quartiles) follow-up of 3.3 (1.8-5.3) years after generator replacement, 68 of 253 (27%) experienced appropriate ICD therapy. Patients with EF ≤ 35% were more likely to experience ICD therapy compared with those with EF > 35% (12% versus 5% per year; hazard ratio, 3.57; P = 0.001). On multivariable analysis, low EF predicted appropriate ICD therapy after generator replacement (hazard ratio, 1.96 [1.35-2.87] per 10% decrement; P = 0.001). Death occurred in 25% of patients 5 years after generator replacement. Mortality was similar in patients with EF ≤ 35% and > 35% (7% versus 5% per year; hazard ratio, 1.10; P = 0.68). Atrial fibrillation (3.24 [1.63-6.43]; P < 0.001) and higher blood urea nitrogen (1.28 [1.14-1.45] per increase of 10 mg/dL; P < 0.001) were associated with mortality.

Conclusions: Although approximately one fourth of patients with a primary prevention ICD and no previous therapy have EF >35% at the time of generator replacement, these patients continue to be at significant risk for appropriate ICD therapy (5% per year). These data may inform decisions on ICD replacement.

Citing Articles

Mid-term clinical outcomes and cardiac function in patients receiving cardiac contractility modulation.

Deak A, Zaidi S, Gangireddy C, Cronin E, Hamad E, Fabrizio C J Interv Card Electrophysiol. 2024; .

PMID: 39210240 DOI: 10.1007/s10840-024-01900-0.


Heart Failure With Improved Ejection Fraction: Prevalence, Predictors, and Guideline-Directed Medical Therapy.

Oommen S, Man R, Talluri K, Nizam M, Kohir T, Aviles M Cureus. 2024; 16(6):e61790.

PMID: 38975458 PMC: 11227107. DOI: 10.7759/cureus.61790.


2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure.

Chung M, Patton K, Lau C, Dal Forno A, Al-Khatib S, Arora V J Arrhythm. 2023; 39(5):681-756.

PMID: 37799799 PMC: 10549836. DOI: 10.1002/joa3.12872.


Incidence and Predictors of Implantable Cardioverter-defibrillator Therapies After Generator Replacement-A Pooled Analysis of 31,640 Patients' Data.

Khanra D, Manivannan S, Mukherjee A, Deshpande S, Gupta A, Rashid W J Innov Card Rhythm Manag. 2023; 13(12):5278-5293.

PMID: 37293556 PMC: 10246925. DOI: 10.19102/icrm.2022.13121.


2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure.

Chung M, Patton K, Lau C, Dal Forno A, Al-Khatib S, Arora V Heart Rhythm. 2023; 20(9):e17-e91.

PMID: 37283271 PMC: 11062890. DOI: 10.1016/j.hrthm.2023.03.1538.


References
1.
Moss A, Greenberg H, Case R, Zareba W, Hall W, Brown M . Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004; 110(25):3760-5. DOI: 10.1161/01.CIR.0000150390.04704.B7. View

2.
Zhang Y, Guallar E, Blasco-Colmenares E, Butcher B, Norgard S, Nauffal V . Changes in Follow-Up Left Ventricular Ejection Fraction Associated With Outcomes in Primary Prevention Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Recipients. J Am Coll Cardiol. 2015; 66(5):524-31. PMC: 4522701. DOI: 10.1016/j.jacc.2015.05.057. View

3.
Gould P, Krahn A . Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA. 2006; 295(16):1907-11. DOI: 10.1001/jama.295.16.1907. View

4.
Goldenberg I, Vyas A, Hall W, Moss A, Wang H, He H . Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008; 51(3):288-96. DOI: 10.1016/j.jacc.2007.08.058. View

5.
Prutkin J, Reynolds M, Bao H, Curtis J, Al-Khatib S, Aggarwal S . Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry. Circulation. 2014; 130(13):1037-43. DOI: 10.1161/CIRCULATIONAHA.114.009081. View